Physician profile
Philip L Rumbaoa
NPI 1083686661
$1,855.02
in general payments reported to CMS, 2019-2025
17 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Phlebology provider received nationally (typical 2025 total: $141).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $407 · 2021: $82.17 · 2022: $711 · 2024: $175 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $395.17 | 2020-2024 | Flexitouch Plus, Entre Plus |
| Boston Scientific Corporation | $337.55 | 2020-2025 | Varithena Administration Pack |
| Bard Peripheral Vascular, INC. | $260.92 | 2021-2022 | |
| Medtronic, INC. | $254.87 | 2022-2025 | Closurefast |
| Biocompatibles, INC. | $122.22 | 2019 | |
| Amgen INC. | $119.35 | 2019-2020 | |
| Venclose INC. | $72.67 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $68.41 | 2025 | |
| Merz North America, INC. | $62.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.67 | 2019-2020 | |
| Astellas Pharma US INC | $24.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18.31 | 2019 | |
| Daiichi Sankyo INC. | $14.87 | 2019 | |
| Lilly USA, LLC | $12.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $12.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Rumbaoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.